YFYoshihiro Fujimori

Yoshihiro Fujimori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshihiro Fujimori has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroyasu Ogawa

    Division of Hematology, Department of Internal Medicine, Laboratory of Cell Transplantation, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan

    5 shared publications
  • Hiroshi Hara

    Uegahara Hospital, Nishinomiya

    4 shared publications
  • Eizo Kakishita

    Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

    3 shared publications
  • Haruki Okamura

    Laboratory of Host Defences, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan

    3 shared publications
  • Kenji Nakanishi

    Department of Immunology and Medical Zoology, Hyogo College of Medicine, Nishinomiya, Japan

    3 shared publications
  • Masaya Okada

    Division of Hematology, Department of Internal Medicine, Laboratory of Cell Transplantation, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan

    3 shared publications

Latest Publications

  • Open Access

    Aldehyde dehydrogenase activity in cryopreserved cord blood cells for quality assessment prior to transplantation

    by Junko Ikemoto, Satoshi Yoshihara, Tamami Kobayashi, Shunro Kai, Yoshihiro Fujimori

    In umbilical cord blood transplantation (UCBT), the number of cluster of differentiation (CD)34+ cells and colony‑forming units (CFUs) in the cord blood (CB) graft positively correlate with patient survival. Therefore, these parameters are currently used for quality assessment of the cryopreserved CB cells in the attached segment that is considered representative of the CB in the main bag prior to UCBT. Since aldehyde dehydrogenase (ALDH) activity is high in hematopoietic stem cells, the number of ALDH‑bright (ALDHbr) cells was examined in comparison with the number of CD34+ cells and CFUs for the quality assessment of CB units. In the cryopreserved main bag, the number of ALDHbr cells in the CB unit exhibited positive correlation with the number of CD34+ cells, and with CFU‑granulocytes/macrophages and total CFU counts. Furthermore, the concentration of ALDHbr cells in the cryopreserved attached segment was not significantly different compared to that of the main bag, suggesting that the attached segment is representative of the main bag. In conclusion, the present study suggested that ALDHbr cell counts in the cryopreserved attached segments may serve as a quality assessment indicator for CB units prior to UCBT.


  • Blood supply during Japan's 1995 Hanshin-Awaji Earthquake

    by Yoshihiro Fujimori, Yoshihiro Bouike, Kenneth Nollet, Hitoshi Miki


  • Recombinant human soluble thrombomodulin attenuates FK506-induced endothelial dysfunction through prevention of Akt inactivation

    by Ryoji Eguchi, Yoshihiro Fujimori, Masaya Okada, Hiroya Tamaki, Ichiro Wakabayashi, Hiroyasu Ogawa


  • Open Access

    Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells

    by Ryoji Eguchi, Shuji Kubo, Hiromi Takeda, Toshiro Ohta, Chiharu Tabata, Hiroyasu Ogawa, Takashi Nakano, Yoshihiro Fujimori

    Malignant mesothelioma is an aggressive tumor arising from mesothelial cells of serous membranes. Src family kinases (SFKs) have a pivotal role in cell adhesion, proliferation, survival and apoptosis. Here, we examined the effect of SFK inhibitors in NCI-H2052, ACC-MESO-4 and NCI-H28 cells, mesothelioma cell lines and Met5A, a human non-malignant mesothelial cell line. We found that PP2, a selective SFK inhibitor, inhibited SFK activity and induced apoptosis mediated by caspase-8 in NCI-H28 but not Met5A, NCI-H2052 and ACC-MESO-4 cells. Src, Yes, Fyn and Lyn protein, which are members of the SFK, were expressed in these cell lines, whereas NCI-H28 cells were deficient in Fyn protein. Small interfering RNA (siRNA) targeting Fyn facilitated PP2-induced apoptosis mediated by caspase-8 in NCI-H2052 and ACC-MESO-4 cells. PP2 reduced Lyn protein levels and suppressed SFK activity in all mesothelioma cell lines. Lyn siRNA induced caspase-8 activation and apoptosis in NCI-H28 cells but not in NCI-H2052 and ACC-MESO-4 cells. However, double RNA interference knockdown of Fyn and Lyn induced apoptosis accompanied by caspase-8 activation in NCI-H2052 and ACC-MESO-4 cells. Dasatinib, an inhibitor of multi-tyrosine kinases including SFK, also inhibited SFK activity and induced reduction of Lyn protein levels, caspase-8 activation and apoptosis in NCI-H28 cells but not in other cell lines. Present study suggests that SFK inhibitors induce caspase-8-dependent apoptosis caused by reduction of Lyn protein in Fyn-deficient mesothelioma cells.


  • Heme Oxygenase-1 Promoter Polymorphism is Associated with Risk of Malignant Mesothelioma

    by Aki Murakami, Yoshihiro Fujimori, Yoshie Yoshikawa, Shusai Yamada, Kunihiro Tamura, Noriko Hirayama, Takayuki Terada, Kozo Kuribayashi, Chiharu Tabata, Kazuya Fukuoka, et al.

    Background Malignant mesothelioma is an aggressive tumor of serosal surfaces that is closely associated with asbestos exposure which induces oxidative stress. Heme oxygenase (HO)-1, a rate-limiting enzyme of heme degradation, plays a protective role against oxidative stress. The HO-1 gene promoter carries (GT)n repeats whose number is inversely related to transcriptional activity of the HO-1 gene. Methods To investigate the relationship between the length polymorphism of (GT)n repeats and mesothelioma susceptibility, we analyzed the HO-1 promoter in 44 asbestos-exposed subjects without mesothelioma and 78 asbestos-exposed subjects with mesothelioma using PCR-based genotyping. Results The number of repeats ranged from 16 to 38, with two peaks at 23 and 30 repeats. Polymorphisms of (GT)n repeats were grouped into two classes of alleles, short (S) (<24) and long (L) (≥24), and three genotypes: L/L, L/S, and S/S. The proportions of allele frequencies in class L as well as genotypic frequencies of L allele carriers (L/L and L/S) were significantly higher in the asbestos-exposed subjects with mesothelioma than in those without mesothelioma. Conclusion The findings of this study suggest that long (GT)n repeats in the HO-1 gene promoter are associated with a higher risk of malignant mesothelioma in the Japanese population.


  • Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene

    by Masaya Okada, Atsushi Satake, Katsuji Kaida, Kyoko Taniguchi, Satoshi Yoshihara, Kazuhiro Ikegame, Hiroya Tamaki, Toshihiro Soma, Yoshihiro Fujimori, Hiroyasu Ogawa

    Chronic myelogenous leukemia (CML) is characterized by Philadelphia (Ph) chromosome with a chimeric gene BCR-ABL created by reciprocal t(9:22) (q34;q11) translocation. Variant Ph chromosome translocations involving chromosomes other than 9 and 22 are found in 5-10% of CML cases. We here report a CML patient who carries a four-way Ph chromosome translocation, t(9;22;15;19) (q34;q11;q15;q13). The patient was diagnosed in 1997 and initially treated with hydroxyurea. In 2002, treatment with imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained at the levels of 42-65%, indicating imatinib failure. In 2006, the point mutations of F359I and L387M were detected in BCR/ABL gene, which may be related to imatinib failure. Treatment with nilotinib, a TKI with high target specificity, was then started which resulted in durable major molecular response. Administration of nilotinib offered an effective treatment in a CML patient with variant Ph chromosome translocations and BCR-ABL point mutations after imatinib failure.


  • CD318/CUB-domain-containing protein 1 expression on cord blood hematopoietic progenitors

    by Hiromi Takeda, Yoshihiro Fujimori, Shunro Kai, Hiroyasu Ogawa, Takashi Nakano

    CUB-domain-containing protein 1 (CDCP1)/CD318 is a single transmembrane molecule highly expressed in colorectal cancer and leukemia. It has also been shown to be expressed in hematopoietic progenitor cells. In this study, we analyzed the expression of CD318 on cord blood hematopoietic stem and progenitor cells. Cord blood mononuclear cells were depleted of mature blood cell linage (Lin)-positive cells and then Lin-negative cells were sorted by flow cytometry based on the expression of CD34 and CD318. Analysis of sorted cells by colony-forming assay showed that CD34+CD318+ cells produced more mixed colony forming units and erythroid burst forming unit-derived colonies than CD34+CD318− cells. These colonies were also produced by CD34−CD318+ and CD34−CD318− cells, but were generally fewer in number. When sorted cells were cultured on a monolayer of human mesenchymal stem cells, CD34+CD318+ cells proliferated more abundantly than CD34+CD318− cells, while CD34−CD318+ and CD34−CD318− cells failed to proliferate. Transplantation of CD34+CD318+ cells into non-obese diabetic/severe combined immunodeficient disease (NOD/SCID) mice resulted in efficient reconstitution of human cells, indicating that CD34+CD318+ cells possess strong SCID-repopulating cell activity. These findings suggest that the co-expression of CD34 and CD318 identifies the immature character of hematopoietic stem cells.


  • Reduced-Intensity Conditioning Followed by Unrelated Umbilical Cord Blood Transplantation for Advanced Hematologic Malignancies: Rapid Engraftment in Bone Marrow

    by Mahito Misawa, Shunro Kai, Masaya Okada, Toshiyuki Nakajima, Kaori Nomura, Takeshi Wakae, Akinari Toda, Hisayuki Itoi, Hiroyuki Takatsuka, Takeyoshi Itsukuma, et al.

    Reduced-intensity (RI) conditioning followed by cord blood transplantation (CBT) is a new treatment modality, but failure to engraft is a major concern. We describe 12 patients with advanced hematologic malignancies who underwent RI conditioning and CBT with a conditioning regimen consisting of 200 mg/m2 fludarabine (Flu), 50 mg/kg cyclophosphamide (CY), and 3 Gy total body irradiation (TBI). Cyclosporin A and/or methotrexate were used for graft-versus-host disease prophylaxis. Cord blood grafts were not mismatched for more than 2 serologically defined HLA alleles but were later found by high-resolution DNA typing to be mismatched for 2 to 4 alleles in most cases. Short tandem repeat analysis of bone marrow cells at day 14 showed complete donor chimerism in 6 of the patients and mixed chimerism in 5, indicating rapid engraftment in the bone marrow, whereas the remaining patient experienced graft rejection. Neutrophil recovery was achieved at a median of day 17 (range, days 11-24) in 10 of the 11 patients with marrow chimerism at day 14. Of these 10 patients, however, transplantation-related mortality within 100 days occurred in 4 patients who showed failed platelet recovery and a lack of durable engraftment. Overall survival and disease-free survival rates were 41.7% and 33.3%, respectively.These results show that CB mismatched at 2 to 4 HLA alleles and transplanted with the Flu/CY/3 Gy TBI regimen is able to engraft in the bone marrow as early as day 14.


  • Interferon-gamma production by human cord blood monocyte-derived dendritic cells

    by Nobuko Yamaguchi, Yoshihiro Fujimori, Yuka Fujibayashi, Ikuyo Kasumoto, Haruki Okamura, Kenji Nakanishi, Hiroshi Hara

    Interferon (IFN)-γ is produced by T cells and natural killer cells and activates monocytes and dendritic cells (DCs). Recently, IFN-γ has been shown to be produced by mouse DCs following stimulation with interleukin (IL)-12, which is markedly augmented by the addition of IL-18. We here analyzed whether human DCs secrete IFN-γ in response to IL-12 and/or IL-18. Human immature DCs, generated from cord blood CD14+ monocytes by treating with granulocyte–macrophage colony-stimulating factor and IL-4, were incubated with IL-12 and/or IL-18 and assayed for IFN-γ production. IL-12, but not IL-18, weakly induced IFN-γ production, while IL-12 together with IL-18 induced high levels of IFN-γ production. Similar results were obtained with mature DCs, although levels of IFN-γ production were less than those in immature DCs. Also with mature and immature DCs, IL-12 upregulated the expression of IL-18 receptor α (Rα), and costimulation with IL-12 and IL-18 upregulated CD40 expression. Anti-IL-18Rα antibody abrogated both the IFN-γ induction and the CD40 upregulation by IL-12 plus IL-18. These findings suggest that IL-12 upregulates IL-18Rα expression on human DCs and acts synergistically with IL-18 to induce high levels of IFN-γ, which subsequently enhances CD40 expression on DCs in an autocrine manner.


  • Short Communication: Increased Expression of Interleukin-18 Receptor on T Lymphocytes in Patients with Acute Graft-versus-Host Disease After Allogeneic Bone Marrow Transplantation

    by Yoshihiro Fujimori, Tomohiro Yoshimoto, Kiyoshi Matsui, Hiroko Tsutsui, Takahiro Okamoto, Shin-Ichiro Kashiwamura, Toshikazu Hada, Haruki Okamura, Eizo Kakishita, Hiroshi Hara, et al.

    Acute graft-versus-host disease (aGVHD), a potentially fatal side effect of allogeneic bone marrow transplantation (BMT), is initiated by the action of donor-derived T lymphocytes. We have shown previously that aGVHD is associated with elevated serum levels of interleukin-18 (IL-18). In this study, we analyzed the expression of the IL-18 receptor (IL-18R) on T lymphocytes of BMT patients with aGVHD. Flow cytometric analysis showed that in healthy subjects, a small population of CD4+ T cells expressed IL-18Ralpha, whereas a relatively large population of CD8+ T cells expressed IL-18Ralpha. In aGVHD patients, there were marked increases in the proportion of CD4+ or CD8+ T cells that express IL-18Ralpha. RT-PCR assays showed elevation of IL-18Ralpha and IL-18Rbeta mRNA levels in CD8+ T cells in aGVHD patients. These findings suggest that the expression of IL-18R is upregulated in T cells in patients with aGVHD and that the IL-18/IL-18R system is active during aGVHD.